The Fly

Axsome Therapeutics study met primary, secondary endpoints, says Guggenheim

Guggenheim analyst Yatin Suneja made no change to the firm’s Buy rating on Axsome Therapeutics after the company announced that the Phase III ACCORD trial evaluating AXS-05 in Alzheimer’s disease agitation met its primary and secondary endpoints. The announcement came as a "pleasant surprise," as expectations were low, and Suneja expects the stock to be up significantly on the news, he tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More